Bioreactor Expansion of Human Mesenchymal Stem Cells According to GMP Requirements

  • Christiane L. Elseberg
  • Denise Salzig
  • Peter Czermak
Part of the Methods in Molecular Biology book series (MIMB, volume 1283)


In cell therapy, the use of autologous and allogenic human mesenchymal stem cells is rising. Accordingly, the supply of cells for clinical applications in highest quality is required. As hMSCs are considered as an advanced therapy medicinal products (ATMP), they underlie the requirements of GMP and PAT according to the authorities (FDA and EMA). The production process of these cells must therefore be documented according to GMP, which is usually performed via a GMP protocol based on standard operating procedures. This chapter provides an example of such a GMP protocol for hMSC, here a genetically modified allogenic cell line, based on a production process in a microcarrier-based stirred tank reactor including process monitoring according to PAT and final product quality assurance.


hMSC GMP protocol SOP PAT Authorities 


  1. 1.
    Hambor JE (2012) Bioreactor design and bioprocess controls for industrialited cell processing. BioProcess Int 10(6):22–33Google Scholar
  2. 2.
    Keating A (2012) Mesenchymal stromal cells: new directions. Cell Stem Cell 10:709–717CrossRefPubMedGoogle Scholar
  3. 3.
    Salzig D, Ehlicke F, Dorresteijn A, Czermak P (2011) Potential of mesenchymal stem cells for regeneration of intervertebral disc. Biomaterialien 12(1–4):198Google Scholar
  4. 4.
    Oppermann T, Leber J, Elseberg C, Salzig D, Czermak P (2014) hMSC production in disposable bioreactors in compliance with cGMP guidelines and PAT. Am Pharmaceut Rev Bioprocess 4Google Scholar
  5. 5.
    Jung S, Panchalingam KM, Wuerth RD, Rosenberg L, Nehie LA (2012) Large-scale production of human mesenchymal stem cells for clinical applications. Biotechnol Appl Biochem 59(2):106–120CrossRefPubMedGoogle Scholar
  6. 6.
    Chen AK, Reuveny S, Oh SK (2013) Application of human mesenchymal and pluripotent stem cell microcarrier cultures in cellular therapy: achievements and future direction. Biotechnol Adv 31(7):1032–1046CrossRefPubMedGoogle Scholar
  7. 7.
    Reicin C, McMahon E, Chung C (2012) Stem cell therapy regulation in Canada: implications of the prochymal approval. Westlaw J 28:1–4Google Scholar
  8. 8.
    Wang S, Qu X, Zhao R (2012) Clinical applications of mesenchymal stem cells. J Hematol Oncol 5:1–9CrossRefGoogle Scholar
  9. 9.
    English K, French A, Wood K (2010) Mesenchymal stromal cells: facilitators of successful transplantation? Cell Stem Cell 7:431–442CrossRefPubMedGoogle Scholar
  10. 10.
    Lindgren CG (2009) Standard operating procedures. In: Gee A (ed) Cell therapy: cGMP facilities and manufacturing. Springer, New York, NYGoogle Scholar
  11. 11.
    Unger C, Skottman H, Blomberg P, Dilber M, Hovatta O (2008) Good manufacturing practice and clinical-grade human embryonic stem cell lines. Hum Mol Genet 17(1):48–53CrossRefGoogle Scholar
  12. 12.
    Salzig D, Schmiermund A, Pino-Grace P, Elseberg C, Weber C, Czermak P (2013) Enzymatic detachment of therapeutic mesenchymal stromal cells grown on glass carriers in a bioreactor. Open Biomed Eng J 7:147–158CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Cierpka K, Elseberg C, Niss K, Kassem M, Salzig D, Czermak P (2013) hMSC production in disposable bioreactors with regards to GMP and PAT. Chem Ing Tech 85(1–2):67–75CrossRefGoogle Scholar
  14. 14.
    Weber C, Pohl S, Freimark D, Poertner R, Pino-Grace P, Wallrapp C, Geigle P, Czermak P (2010) Expansion of human mesenchymal stem cells in a fixed-bed bioreactor system based on non-porous glass carrier: part A—inoculation, cultivation, and cell harvest procedures. Int J Artif Org 33(8):512–525Google Scholar
  15. 15.
    Weber C, Pohl S, Poertner R, Pino-Grace P, Wallrapp C, Geigle P, Czermak P (2010) Expansion of human mesenchymal stem cells in a fixed-bed bioreactor system based on non-porous glass carrier: part B—modeling and scale up. Int J Artif Org 33(11):782–795Google Scholar
  16. 16.
    Weber C, Pohl S, Poertner R, Pino-Grace P, Freimark D, Wallrapp C, Geigle P, Czermak P (2010) Production process for stem cell based therapeutic implants: expansion of the production cell line and cultivation of encapsulated cells. Adv Biochem Eng Biotechnol 123:143–162PubMedGoogle Scholar
  17. 17.
    Weber C, Pohl S, Poertner R, Wallrapp C, Geigle P, Czermak P (2009) Fixed bed reactor systems for the expansion and differentiation of stem cells for cell therapy. Int J Artif Organs 32(7):418Google Scholar
  18. 18.
    Czermak P, Weber C, Pohl S, Poertner R, Wallrapp C, Geigle P (2008) Development of a production process for stem cell based cell therapeutic implants. Int J Artif Organs 31(7):584Google Scholar
  19. 19.
    Czermak P, Weber C, Salzig D, Pörtner R, Wallrapp C, Hudel K (2011) Stammzellbasierte zelltherapeutische Implantate: Entwicklung eines Herstellungs- und Kryokonservierungsverfahrens. Biomaterialien 12(1–4):187Google Scholar
  20. 20.
    Freimark D, Sehl C, Grein T, Weber C, Hudel K, Glasmacher B, Czermak P (2010) Stem cell based therapeutic implants: production and storage. Int J Artif Organs 33(7):426Google Scholar
  21. 21.
    Justice C, Leber J, Salzig D, Wallrapp C, Kassem M, Kraume M, Czermak P (2012) Microcarrier based expansion process of hMSCs in highly vital and non-differentiated quality. Int J Artif Organs 35(2):39–107Google Scholar
  22. 22.
    Druzinec D, Weiss K, Elseberg C, Salzig D, Kraume M, Poertner R, Czermak P (2014) Process analytical technology (PAT) in insect and mammalian cell culture processes: dielectric spectroscopy and focused beam reflectance measurement (FBRM). Methods Mol Biol 1104:313–341CrossRefPubMedGoogle Scholar
  23. 23.
    Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315–317CrossRefPubMedGoogle Scholar
  24. 24.
    Justice C, Leber J, Freimark D, Pino-Grace P, Kraume M, Czermak P (2011) Online- and offline-monitoring of stem cell expansion on microcarrier. Cytotechnol 63(4):325–335. doi: 10.1007/s10616-011-9359-4 CrossRefGoogle Scholar
  25. 25.
    Justice C, Brix A, Freimark D, Kraume M, Pfromm P, Eichenmueller B, Czermak P (2011) Process control in cell culture technology using dielectric spectroscopy. Biotechnol Adv 29(4):391–401CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Christiane L. Elseberg
    • 1
  • Denise Salzig
    • 1
  • Peter Czermak
    • 1
    • 2
    • 3
  1. 1.Institute of Bioprocess Engineering and Pharmaceutical TechnologyUniversity of Applied Sciences MittelhessenGiessenGermany
  2. 2.Department of Chemical EngineeringFaculty of Engineering, Kansas State UniversityManhattanUSA
  3. 3.Faculty of Biology and ChemistryJustus-Liebig-University GiessenGiessenGermany

Personalised recommendations